FY2025 EPS Estimates for JSPR Boosted by Cantor Fitzgerald

Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will post earnings per share of ($4.17) for the year, up from their prior forecast of ($4.24). The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share.

JSPR has been the subject of several other reports. Royal Bank of Canada lowered their price objective on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research note on Thursday, January 9th. BMO Capital Markets started coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. HC Wainwright reduced their target price on shares of Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, January 10th. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $38.00 target price for the company. Finally, JMP Securities restated a "market outperform" rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $62.50.

Remove Ads

Jasper Therapeutics Trading Down 1.7 %

NASDAQ JSPR traded down $0.09 during trading hours on Thursday, hitting $5.28. The company's stock had a trading volume of 246,948 shares, compared to its average volume of 266,384. The company has a market capitalization of $79.21 million, a PE ratio of -1.11 and a beta of 2.23. Jasper Therapeutics has a 52 week low of $4.55 and a 52 week high of $31.01. The company's 50-day simple moving average is $7.99 and its two-hundred day simple moving average is $16.28.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35).

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently modified their holdings of JSPR. BNP Paribas Financial Markets lifted its stake in Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after purchasing an additional 1,698 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company's stock valued at $129,000 after buying an additional 3,873 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company's stock worth $159,000 after acquiring an additional 3,828 shares during the period. EntryPoint Capital LLC purchased a new stake in Jasper Therapeutics in the 4th quarter worth about $223,000. Finally, Jane Street Group LLC bought a new stake in Jasper Therapeutics in the 3rd quarter valued at about $251,000. Hedge funds and other institutional investors own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.